{"transactions":[{"id":722,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":609,"kind":"person","name":"Lundquist Kevin Michael","position":1,"cik":"0002074701","reported_name":"Lundquist Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-02T20:32:01.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted by Outlook Therapeutics, Inc. (the \"Issuer\") as an inducement material to the Reporting Person's entry into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). 25% of the shares subject to the option shall vest on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":500000,"derivative":{"exercise_price":0.63,"expiration_date":"2036-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0002074701-26-000005","document":"form4-09022026_080957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2074701/000207470126000005/form4-09022026_080957.xml","form_type":"4"}},{"id":686457,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23225,"kind":"person","name":"Jahr Robert Charles","position":1,"cik":"0002076177","reported_name":"Jahr Robert Charles","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-08-15T00:57:45.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":151515,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant."}],"balance_after":151515,"derivative":{"exercise_price":1.1,"exercise_date":"2026-08-14","expiration_date":"2031-08-14","underlying":"Common Stock","underlying_shares":151515},"source":{"system":"sec-edgar","filing":"0001104659-26-097406","document":"tm2623340-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926097406/tm2623340-2_4seq1.xml","form_type":"4"}},{"id":686456,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23225,"kind":"person","name":"Jahr Robert Charles","position":1,"cik":"0002076177","reported_name":"Jahr Robert Charles","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:57:45.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":151515,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant."}],"balance_after":151515,"source":{"system":"sec-edgar","filing":"0001104659-26-097406","document":"tm2623340-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926097406/tm2623340-2_4seq1.xml","form_type":"4"}},{"id":686984,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2026-08-14T23:52:49.000Z","date":"2026-08-12","kind":"purchase","planned":false,"acquired":true,"shares":2525252,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2026, the Issuer entered into an underwriting agreement with Piper Sandler & Co. and BTIG, LLC, as representatives of the several underwriters named therein, relating to an underwritten public offering by the Issuer of shares of its common stock and accompanying warrants to purchase shares of common stock at a combined public offering price of $0.99 per share of common stock and accompanying warrant. The offering closed on August 14, 2026. The price reported in Table I above represents the combined public offering price for one share of common stock and one accompanying warrant to purchase one share of common\nstock; no separate consideration was paid for the accompanying warrants, and accordingly the price of the derivative security reported in Table II above is $0.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031. The warrants are subject to a beneficial ownership limitation that prohibits exercise to the extent the holder, together with its affiliates and other attribution parties, would beneficially own more than the applicable percentage of the Issuer's outstanding common stock immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031. The warrants are subject to a beneficial ownership limitation that prohibits exercise to the extent the holder, together with its affiliates and other attribution parties, would beneficially own more than the applicable percentage of the Issuer's outstanding common stock immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting\nPersons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2525252,"derivative":{"exercise_price":1.1,"exercise_date":"2026-08-14","expiration_date":"2031-08-14","underlying":"Common Stock","underlying_shares":2525252},"source":{"system":"sec-edgar","filing":"0000899140-26-000894","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000894/form4.xml","form_type":"4"}},{"id":686983,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T23:52:49.000Z","date":"2026-08-12","kind":"purchase","planned":false,"acquired":true,"shares":2525252,"price":0.99,"value":2499999.48,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2026, the Issuer entered into an underwriting agreement with Piper Sandler & Co. and BTIG, LLC, as representatives of the several underwriters named therein, relating to an underwritten public offering by the Issuer of shares of its common stock and accompanying warrants to purchase shares of common stock at a combined public offering price of $0.99 per share of common stock and accompanying warrant. The offering closed on August 14, 2026. The price reported in Table I above represents the combined public offering price for one share of common stock and one accompanying warrant to purchase one share of common\nstock; no separate consideration was paid for the accompanying warrants, and accordingly the price of the derivative security reported in Table II above is $0.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting\nPersons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":24617320,"source":{"system":"sec-edgar","filing":"0000899140-26-000894","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000894/form4.xml","form_type":"4"}},{"id":686610,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants (right to buy)","published_at":"2026-08-14T23:39:28.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":101010,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant."}],"balance_after":101010,"derivative":{"exercise_price":1.1,"exercise_date":"2026-08-14","expiration_date":"2031-08-14","underlying":"Common Stock","underlying_shares":101010},"source":{"system":"sec-edgar","filing":"0001649989-26-000009","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000164998926000009/primary_doc.xml","form_type":"4"}},{"id":686609,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T23:39:28.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":101010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant."}],"balance_after":106956,"source":{"system":"sec-edgar","filing":"0001649989-26-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000164998926000009/primary_doc.xml","form_type":"4"}},{"id":701307,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T19:19:37.000Z","date":"2026-07-29","kind":"purchase","planned":false,"acquired":true,"shares":95398,"price":1.0482,"value":99996.1836,"ownership":{"direct":true},"balance_after":220972,"source":{"system":"sec-edgar","filing":"0001649989-26-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000008/primary_doc.xml","form_type":"4"}},{"id":703960,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-23T23:49:45.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":210078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted to Mr. Kenyon on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Kenyon's continuing service with the Issuer through such vesting date."}],"balance_after":210078,"derivative":{"exercise_price":1.4304,"exercise_date":"2027-07-21","expiration_date":"2036-07-21","underlying":"Common Stock","underlying_shares":210078},"source":{"system":"sec-edgar","filing":"0001649989-26-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000164998926000007/primary_doc.xml","form_type":"4"}},{"id":703926,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23225,"kind":"person","name":"Jahr Robert Charles","position":1,"cik":"0002076177","reported_name":"Jahr Robert Charles","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-23T23:34:19.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted to Mr. Jahr on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Jahr's continuing service with the Issuer through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":1.4304,"exercise_date":"2027-07-21","expiration_date":"2036-07-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001649989-26-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000006/primary_doc.xml","form_type":"4"}},{"id":750810,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T22:03:16.000Z","date":"2026-06-02","kind":"purchase","planned":false,"acquired":true,"shares":29000,"price":0.8326,"value":24145.4,"ownership":{"direct":true},"balance_after":66167,"source":{"system":"sec-edgar","filing":"0001649989-26-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000005/primary_doc.xml","form_type":"4"}},{"id":757130,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"ten_percent_owner":true}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (right to buy)","published_at":"2026-06-02T01:30:12.000Z","date":"2026-05-28","kind":"purchase","planned":false,"acquired":true,"shares":8571428,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The transactions reported in Table II above involved the amendment of the outstanding warrants issued on May 27, 2025 to reduce the exercise price from $1.40 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transactions reported in Table II above involved the amendment of the outstanding warrants issued on May 27, 2025 to reduce the exercise price from $1.40 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8571428,"derivative":{"exercise_price":0.5855,"exercise_date":"2025-05-27","expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":8571428},"source":{"system":"sec-edgar","filing":"0000899140-26-000620","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000620/form4.xml","form_type":"4"}},{"id":757129,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"ten_percent_owner":true}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (right to buy)","published_at":"2026-06-02T01:30:12.000Z","date":"2026-05-28","kind":"other","planned":false,"acquired":false,"shares":8571428,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The transactions reported in Table II above involved the amendment of the outstanding warrants issued on May 27, 2025 to reduce the exercise price from $1.40 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transactions reported in Table II above involved the amendment of the outstanding warrants issued on May 27, 2025 to reduce the exercise price from $1.40 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.4,"exercise_date":"2025-05-27","expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":8571428},"source":{"system":"sec-edgar","filing":"0000899140-26-000620","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000620/form4.xml","form_type":"4"}},{"id":757128,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"ten_percent_owner":true}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (right to buy)","published_at":"2026-06-02T01:30:12.000Z","date":"2026-05-28","kind":"purchase","planned":false,"acquired":true,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The transactions reported in Table II above involved the amendment of the outstanding Tranche B warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported in Table II above involved the amendment of the outstanding Tranche B warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3458571,"derivative":{"exercise_price":0.5855,"exercise_date":"2025-03-11","expiration_date":"2030-03-11","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000899140-26-000620","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000620/form4.xml","form_type":"4"}},{"id":757127,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"ten_percent_owner":true}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (right to buy)","published_at":"2026-06-02T01:30:12.000Z","date":"2026-05-28","kind":"other","planned":false,"acquired":false,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The transactions reported in Table II above involved the amendment of the outstanding Tranche B warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported in Table II above involved the amendment of the outstanding Tranche B warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.26,"exercise_date":"2025-03-11","expiration_date":"2030-03-11","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000899140-26-000620","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000620/form4.xml","form_type":"4"}},{"id":757126,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"ten_percent_owner":true}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (right to buy)","published_at":"2026-06-02T01:30:12.000Z","date":"2026-05-28","kind":"purchase","planned":false,"acquired":true,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transactions reported in Table II above involved the amendment of the outstanding Tranche A warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported in Table II above involved the amendment of the outstanding Tranche A warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3458571,"derivative":{"exercise_price":0.5855,"exercise_date":"2025-01-17","expiration_date":"2030-01-17","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000899140-26-000620","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000620/form4.xml","form_type":"4"}},{"id":757125,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"ten_percent_owner":true}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrants (right to buy)","published_at":"2026-06-02T01:30:12.000Z","date":"2026-05-28","kind":"other","planned":false,"acquired":false,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transactions reported in Table II above involved the amendment of the outstanding Tranche A warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported in Table II above involved the amendment of the outstanding Tranche A warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.26,"exercise_date":"2025-01-17","expiration_date":"2030-01-17","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000899140-26-000620","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000620/form4.xml","form_type":"4"}},{"id":757124,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"ten_percent_owner":true}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-06-02T01:30:12.000Z","date":"2026-05-28","kind":"purchase","planned":false,"acquired":true,"shares":8539709,"price":0.5855,"value":4999999.6195,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 28, 2026, GMS Ventures and Investments (\"GMS Ventures\") entered into a securities purchase agreement with Outlook Therapeutics, Inc. (the \"Issuer\") pursuant to which the Issuer agreed to issue and sell 8,539,709 shares of the Issuer's common stock at $0.5855 per share in a registered direct offering for a total purchase price of approximately $5.0 million."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":22092068,"source":{"system":"sec-edgar","filing":"0000899140-26-000620","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000089914026000620/form4.xml","form_type":"4"}},{"id":761234,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-27T19:29:11.000Z","date":"2026-05-27","kind":"purchase","planned":false,"acquired":true,"shares":122174,"price":0.4093,"value":50005.8182,"ownership":{"direct":true},"balance_after":125574,"source":{"system":"sec-edgar","filing":"0001649989-26-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000004/primary_doc.xml","form_type":"4"}},{"id":761233,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-27T19:24:20.000Z","date":"2026-05-26","kind":"purchase","planned":false,"acquired":true,"shares":34000,"price":0.44,"value":14960.0,"ownership":{"direct":true},"balance_after":37167,"source":{"system":"sec-edgar","filing":"0001649989-26-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000003/primary_doc.xml","form_type":"4"}},{"id":761519,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":43781,"kind":"person","name":"THURMAN RANDY H","position":1,"cik":"0001204059","reported_name":"THURMAN RANDY H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-27T19:20:49.000Z","date":"2026-05-26","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.429,"value":2145.0,"ownership":{"direct":true},"balance_after":5593,"source":{"system":"sec-edgar","filing":"0001649989-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1204059/000164998926000002/primary_doc.xml","form_type":"4"}},{"id":761524,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":33645,"kind":"person","name":"HILZINGER KURT J","position":1,"cik":"0001191504","reported_name":"HILZINGER KURT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-27T19:15:05.000Z","date":"2026-05-26","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":0.4413,"value":176520.0,"ownership":{"direct":true},"balance_after":423655,"source":{"system":"sec-edgar","filing":"0001649989-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191504/000164998926000001/primary_doc.xml","form_type":"4"}},{"id":1024029,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":14549,"kind":"person","name":"Haller Julia A","position":1,"cik":"0001656082","reported_name":"Haller Julia A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-04T00:12:17.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":58648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":58648,"derivative":{"exercise_price":1.06,"expiration_date":"2035-10-03","underlying":"Common Stock","underlying_shares":58648},"source":{"system":"sec-edgar","filing":"0001649989-25-000009","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998925000009/primary_doc.xml","form_type":"4"}},{"id":1024028,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":14549,"kind":"person","name":"Haller Julia A","position":1,"cik":"0001656082","reported_name":"Haller Julia A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-04T00:12:17.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000009","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998925000009/primary_doc.xml","form_type":"4"}},{"id":1024294,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":33645,"kind":"person","name":"HILZINGER KURT J","position":1,"cik":"0001191504","reported_name":"HILZINGER KURT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T23:55:24.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":90638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2024 Plan in lieu of $85,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":90638,"derivative":{"exercise_price":1.06,"expiration_date":"2035-10-03","underlying":"Common Stock","underlying_shares":90638},"source":{"system":"sec-edgar","filing":"0001649989-25-000008","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1191504/000164998925000008/primary_doc.xml","form_type":"4"}},{"id":1024293,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":33645,"kind":"person","name":"HILZINGER KURT J","position":1,"cik":"0001191504","reported_name":"HILZINGER KURT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T23:55:24.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000008","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191504/000164998925000008/primary_doc.xml","form_type":"4"}},{"id":1024020,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T23:20:43.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":95969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":95969,"derivative":{"exercise_price":1.06,"expiration_date":"2035-10-03","underlying":"Common Stock","underlying_shares":95969},"source":{"system":"sec-edgar","filing":"0001649989-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998925000006/primary_doc.xml","form_type":"4"}},{"id":1024019,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T23:20:43.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998925000006/primary_doc.xml","form_type":"4"}},{"id":1024288,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":43781,"kind":"person","name":"THURMAN RANDY H","position":1,"cik":"0001204059","reported_name":"THURMAN RANDY H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T23:00:18.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1204059/000164998925000004/primary_doc.xml","form_type":"4"}},{"id":1024018,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T22:52:56.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":117296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2024 Plan in lieu of $110,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":117296,"derivative":{"exercise_price":1.06,"expiration_date":"2035-10-03","underlying":"Common Stock","underlying_shares":117296},"source":{"system":"sec-edgar","filing":"0001649989-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998925000003/primary_doc.xml","form_type":"4"}},{"id":1024017,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T22:52:56.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000164998925000003/primary_doc.xml","form_type":"4"}},{"id":1024730,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74560,"kind":"person","name":"Huang Andong","position":1,"cik":"0001815678","reported_name":"Huang Andong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T20:37:02.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":53316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2024 Plan in lieu of $50,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":53316,"derivative":{"exercise_price":1.06,"expiration_date":"2035-10-03","underlying":"Common Stock","underlying_shares":53316},"source":{"system":"sec-edgar","filing":"0001649989-25-000010","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815678/000164998925000010/primary_doc.xml","form_type":"4"}},{"id":1024729,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74560,"kind":"person","name":"Huang Andong","position":1,"cik":"0001815678","reported_name":"Huang Andong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T20:37:02.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000010","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815678/000164998925000010/primary_doc.xml","form_type":"4"}},{"id":1024132,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T19:45:08.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000164998925000007/primary_doc.xml","form_type":"4"}},{"id":1024533,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74553,"kind":"person","name":"Auffarth Gerd","position":1,"cik":"0001649867","reported_name":"Auffarth Gerd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T19:14:54.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":58648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":58648,"derivative":{"exercise_price":1.06,"expiration_date":"2035-10-03","underlying":"Common Stock","underlying_shares":58648},"source":{"system":"sec-edgar","filing":"0001649989-25-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649867/000164998925000005/primary_doc.xml","form_type":"4"}},{"id":1024532,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74553,"kind":"person","name":"Auffarth Gerd","position":1,"cik":"0001649867","reported_name":"Auffarth Gerd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T19:14:54.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":286734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":286734,"derivative":{"exercise_price":1.04,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":286734},"source":{"system":"sec-edgar","filing":"0001649989-25-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649867/000164998925000005/primary_doc.xml","form_type":"4"}},{"id":1089888,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23225,"kind":"person","name":"Jahr Robert Charles","position":1,"cik":"0002076177","reported_name":"Jahr Robert Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-09T21:17:49.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on July 1, 2026, with the remaining shares vesting in 36 equal monthly installments over the following three (3) years, subject to the Reporting Person's Continuous Service to the Issuer through each such vesting date."}],"balance_after":800000,"derivative":{"exercise_price":1.58,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001415889-25-019586","document":"form4-07092025_090745.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588925019586/form4-07092025_090745.xml","form_type":"4"}},{"id":1132030,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-05-28T21:20:21.000Z","date":"2025-05-27","kind":"grant","planned":false,"acquired":true,"shares":8571428,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired in an underwritten public offering, pursuant to which Outlook Therapeutics, Inc. (the \"Issuer\") sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase two shares of common stock, at a purchase price of $1.40 per share and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired in an underwritten public offering, pursuant to which Outlook Therapeutics, Inc. (the \"Issuer\") sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase two shares of common stock, at a purchase price of $1.40 per share and accompanying warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures and Investments (\"GMS Ventures\"). Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8571428,"derivative":{"exercise_price":1.4,"exercise_date":"2025-05-27","expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":8571428},"source":{"system":"sec-edgar","filing":"0000947871-25-000571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787125000571/ownership.xml","form_type":"4"}},{"id":1132029,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-28T21:20:21.000Z","date":"2025-05-27","kind":"grant","planned":false,"acquired":true,"shares":4285714,"price":1.4,"value":5999999.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired in an underwritten public offering, pursuant to which Outlook Therapeutics, Inc. (the \"Issuer\") sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase two shares of common stock, at a purchase price of $1.40 per share and accompanying warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by GMS Ventures and Investments (\"GMS Ventures\"). Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":13552359,"source":{"system":"sec-edgar","filing":"0000947871-25-000571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787125000571/ownership.xml","form_type":"4"}},{"id":1209852,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T00:56:07.000Z","date":"2025-01-17","kind":"exercise","planned":false,"acquired":true,"shares":3458571,"price":2.51,"value":8681013.21,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 22, 2025, the Reporting Persons filed a Form 4 reporting the exercise of certain warrants to purchase shares of the Issuer's common stock. This amendment is being filed to report the receipt of shares of the Issuer's common stock upon the exercise of such warrants and to correct the date of earliest transaction reported."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of a warrant exercise inducement offer letter agreement, dated as of January 16, 2025, by and between Outlook Therapeutics, Inc. (the \"Issuer\") and GMS Ventures and Investments (\"GMS Ventures\"), GMS Ventures agreed to exercise its existing warrant to purchase shares of the Issuer's common stock, par value $0.01 per share (the \"Common Stock\"), at a reduced exercise price of $2.51 per share in exchange for the Company's agreement to issue new warrants to purchase 6,917,142 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9266645,"source":{"system":"sec-edgar","filing":"0000947871-25-000306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787125000306/ownership.xml","form_type":"4/A","original_submission_date":"2025-01-22"}},{"id":1280002,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T21:40:17.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":12323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in three (3) equal installments on each of March 31, 2025, June 30, 2025 and September 30, 2025, subject to the Optionholder's Continuous Service to the Issuer through such vesting date."}],"balance_after":12323,"derivative":{"exercise_price":1.825,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":12323},"source":{"system":"sec-edgar","filing":"0001415889-25-003258","document":"form4-02062025_090213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588925003258/form4-02062025_090213.xml","form_type":"4"}},{"id":1297772,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-01-22T21:11:11.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of a warrant exercise inducement offer letter agreement, dated as of January 16, 2025, by and between Outlook Therapeutics, Inc. (the \"Issuer\") and GMS Ventures and Investments (\"GMS Ventures\"), GMS Ventures agreed to exercise its existing warrant to purchase shares of the Issuer's common stock, par value $0.01 per share (the \"Common Stock\"), at a reduced exercise price of $2.51 per share in exchange for the Issuer's agreement to issue new warrants to purchase 6,917,142 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This warrant will be exercisable upon the effective date (the \"Effective Date\") of an amendment to the Issuer's Certificate of Incorporation increasing the number of authorized shares of Common Stock issuable thereunder and will expire five years following the Effective Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This warrant will be exercisable upon the effective date (the \"Effective Date\") of an amendment to the Issuer's Certificate of Incorporation increasing the number of authorized shares of Common Stock issuable thereunder and will expire five years following the Effective Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3458571,"derivative":{"exercise_price":2.26,"underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000947871-25-000062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787125000062/ownership.xml","form_type":"4"}},{"id":1297771,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-01-22T21:11:11.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of a warrant exercise inducement offer letter agreement, dated as of January 16, 2025, by and between Outlook Therapeutics, Inc. (the \"Issuer\") and GMS Ventures and Investments (\"GMS Ventures\"), GMS Ventures agreed to exercise its existing warrant to purchase shares of the Issuer's common stock, par value $0.01 per share (the \"Common Stock\"), at a reduced exercise price of $2.51 per share in exchange for the Issuer's agreement to issue new warrants to purchase 6,917,142 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3458571,"derivative":{"exercise_price":2.26,"exercise_date":"2025-01-17","expiration_date":"2030-01-17","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000947871-25-000062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787125000062/ownership.xml","form_type":"4"}},{"id":1297770,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-01-22T21:11:11.000Z","date":"2025-01-17","kind":"exercise","planned":false,"acquired":false,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of a warrant exercise inducement offer letter agreement, dated as of January 16, 2025, by and between Outlook Therapeutics, Inc. (the \"Issuer\") and GMS Ventures and Investments (\"GMS Ventures\"), GMS Ventures agreed to exercise its existing warrant to purchase shares of the Issuer's common stock, par value $0.01 per share (the \"Common Stock\"), at a reduced exercise price of $2.51 per share in exchange for the Issuer's agreement to issue new warrants to purchase 6,917,142 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.51,"exercise_date":"2024-03-18","expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000947871-25-000062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787125000062/ownership.xml","form_type":"4"}},{"id":1297769,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-01-22T21:11:11.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of a warrant exercise inducement offer letter agreement, dated as of January 16, 2025, by and between Outlook Therapeutics, Inc. (the \"Issuer\") and GMS Ventures and Investments (\"GMS Ventures\"), GMS Ventures agreed to exercise its existing warrant to purchase shares of the Issuer's common stock, par value $0.01 per share (the \"Common Stock\"), at a reduced exercise price of $2.51 per share in exchange for the Issuer's agreement to issue new warrants to purchase 6,917,142 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3458571,"derivative":{"exercise_price":2.51,"exercise_date":"2024-03-18","expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000947871-25-000062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787125000062/ownership.xml","form_type":"4"}},{"id":1297768,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-01-22T21:11:11.000Z","date":"2025-01-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of a warrant exercise inducement offer letter agreement, dated as of January 16, 2025, by and between Outlook Therapeutics, Inc. (the \"Issuer\") and GMS Ventures and Investments (\"GMS Ventures\"), GMS Ventures agreed to exercise its existing warrant to purchase shares of the Issuer's common stock, par value $0.01 per share (the \"Common Stock\"), at a reduced exercise price of $2.51 per share in exchange for the Issuer's agreement to issue new warrants to purchase 6,917,142 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":7.7,"exercise_date":"2024-03-18","expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000947871-25-000062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787125000062/ownership.xml","form_type":"4"}},{"id":1391406,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":14549,"kind":"person","name":"Haller Julia A","position":1,"cik":"0001656082","reported_name":"Haller Julia A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:18.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":12082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":12082,"derivative":{"exercise_price":5.25,"expiration_date":"2034-10-03","underlying":"Common Stock","underlying_shares":12082},"source":{"system":"sec-edgar","filing":"0001415889-24-024708","document":"form4-10032024_081015.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024708/form4-10032024_081015.xml","form_type":"4"}},{"id":1391405,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":14549,"kind":"person","name":"Haller Julia A","position":1,"cik":"0001656082","reported_name":"Haller Julia A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:18.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":47232,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":47232,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":47232},"source":{"system":"sec-edgar","filing":"0001415889-24-024708","document":"form4-10032024_081015.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024708/form4-10032024_081015.xml","form_type":"4"}},{"id":1391404,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":14549,"kind":"person","name":"Haller Julia A","position":1,"cik":"0001656082","reported_name":"Haller Julia A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:18.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024708","document":"form4-10032024_081015.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024708/form4-10032024_081015.xml","form_type":"4"}},{"id":1391403,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:10.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":19771,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":19771,"derivative":{"exercise_price":5.25,"expiration_date":"2034-10-03","underlying":"Common Stock","underlying_shares":19771},"source":{"system":"sec-edgar","filing":"0001415889-24-024704","document":"form4-10032024_081007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024704/form4-10032024_081007.xml","form_type":"4"}},{"id":1391402,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:10.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":132293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":132293,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":132293},"source":{"system":"sec-edgar","filing":"0001415889-24-024704","document":"form4-10032024_081007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024704/form4-10032024_081007.xml","form_type":"4"}},{"id":1391401,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:10.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024704","document":"form4-10032024_081007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024704/form4-10032024_081007.xml","form_type":"4"}},{"id":1391400,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:09.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":19771,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":19771,"derivative":{"exercise_price":5.25,"expiration_date":"2034-10-03","underlying":"Common Stock","underlying_shares":19771},"source":{"system":"sec-edgar","filing":"0001415889-24-024703","document":"form4-10032024_081005.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024703/form4-10032024_081005.xml","form_type":"4"}},{"id":1391399,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:09.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":134430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":134430,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":134430},"source":{"system":"sec-edgar","filing":"0001415889-24-024703","document":"form4-10032024_081005.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024703/form4-10032024_081005.xml","form_type":"4"}},{"id":1391398,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:09.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024703","document":"form4-10032024_081005.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924024703/form4-10032024_081005.xml","form_type":"4"}},{"id":1391663,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":33645,"kind":"person","name":"HILZINGER KURT J","position":1,"cik":"0001191504","reported_name":"HILZINGER KURT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:07.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":18672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted under the 2024 Plan in lieu of $85,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":18672,"derivative":{"exercise_price":5.25,"expiration_date":"2034-10-03","underlying":"Common Stock","underlying_shares":18672},"source":{"system":"sec-edgar","filing":"0001415889-24-024702","document":"form4-10032024_081003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1191504/000141588924024702/form4-10032024_081003.xml","form_type":"4"}},{"id":1391662,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":33645,"kind":"person","name":"HILZINGER KURT J","position":1,"cik":"0001191504","reported_name":"HILZINGER KURT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:07.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":105151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":105151,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":105151},"source":{"system":"sec-edgar","filing":"0001415889-24-024702","document":"form4-10032024_081003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1191504/000141588924024702/form4-10032024_081003.xml","form_type":"4"}},{"id":1391661,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":33645,"kind":"person","name":"HILZINGER KURT J","position":1,"cik":"0001191504","reported_name":"HILZINGER KURT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:07.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024702","document":"form4-10032024_081003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191504/000141588924024702/form4-10032024_081003.xml","form_type":"4"}},{"id":1391656,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":43781,"kind":"person","name":"THURMAN RANDY H","position":1,"cik":"0001204059","reported_name":"THURMAN RANDY H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:05.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":89549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":89549,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":89549},"source":{"system":"sec-edgar","filing":"0001415889-24-024701","document":"form4-10032024_081001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1204059/000141588924024701/form4-10032024_081001.xml","form_type":"4"}},{"id":1391655,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":43781,"kind":"person","name":"THURMAN RANDY H","position":1,"cik":"0001204059","reported_name":"THURMAN RANDY H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T00:30:05.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024701","document":"form4-10032024_081001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1204059/000141588924024701/form4-10032024_081001.xml","form_type":"4"}},{"id":1391538,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T21:22:40.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":71169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":71169,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":71169},"source":{"system":"sec-edgar","filing":"0001415889-24-024711","document":"form4-10042024_011036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000141588924024711/form4-10042024_011036.xml","form_type":"4"}},{"id":1391537,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T21:22:40.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024711","document":"form4-10042024_011036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000141588924024711/form4-10042024_011036.xml","form_type":"4"}},{"id":1392179,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74560,"kind":"person","name":"Huang Andong","position":1,"cik":"0001815678","reported_name":"Huang Andong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T20:30:16.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":10984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted under the 2024 Plan in lieu of $50,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":10984,"derivative":{"exercise_price":5.25,"expiration_date":"2034-10-03","underlying":"Common Stock","underlying_shares":10984},"source":{"system":"sec-edgar","filing":"0001415889-24-024707","document":"form4-10032024_081013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815678/000141588924024707/form4-10032024_081013.xml","form_type":"4"}},{"id":1392178,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74560,"kind":"person","name":"Huang Andong","position":1,"cik":"0001815678","reported_name":"Huang Andong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T20:30:16.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":23509,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":23509,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":23509},"source":{"system":"sec-edgar","filing":"0001415889-24-024707","document":"form4-10032024_081013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815678/000141588924024707/form4-10032024_081013.xml","form_type":"4"}},{"id":1392177,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74560,"kind":"person","name":"Huang Andong","position":1,"cik":"0001815678","reported_name":"Huang Andong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T20:30:16.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024707","document":"form4-10032024_081013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815678/000141588924024707/form4-10032024_081013.xml","form_type":"4"}},{"id":1391952,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74553,"kind":"person","name":"Auffarth Gerd","position":1,"cik":"0001649867","reported_name":"Auffarth Gerd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T20:30:14.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":12082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":12082,"derivative":{"exercise_price":5.25,"expiration_date":"2034-10-03","underlying":"Common Stock","underlying_shares":12082},"source":{"system":"sec-edgar","filing":"0001415889-24-024706","document":"form4-10032024_081011.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1649867/000141588924024706/form4-10032024_081011.xml","form_type":"4"}},{"id":1391951,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74553,"kind":"person","name":"Auffarth Gerd","position":1,"cik":"0001649867","reported_name":"Auffarth Gerd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T20:30:14.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":29493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":29493,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":29493},"source":{"system":"sec-edgar","filing":"0001415889-24-024706","document":"form4-10032024_081011.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649867/000141588924024706/form4-10032024_081011.xml","form_type":"4"}},{"id":1391950,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74553,"kind":"person","name":"Auffarth Gerd","position":1,"cik":"0001649867","reported_name":"Auffarth Gerd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T20:30:14.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":56636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the \"2024 Plan\") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":56636,"derivative":{"exercise_price":5.22,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":56636},"source":{"system":"sec-edgar","filing":"0001415889-24-024706","document":"form4-10032024_081011.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649867/000141588924024706/form4-10032024_081011.xml","form_type":"4"}},{"id":1397803,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-30T20:53:23.000Z","date":"2024-09-26","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.6892,"value":28446.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024."}],"balance_after":5946,"source":{"system":"sec-edgar","filing":"0001415889-24-024093","document":"form4-09302024_080919.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000141588924024093/form4-09302024_080919.xml","form_type":"4"}},{"id":1540058,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":91943,"kind":"organization","name":"Syntone Ventures LLC","position":1,"cik":"0001814394","reported_name":"Syntone Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-17T20:21:17.000Z","date":"2024-04-15","kind":"purchase","planned":false,"acquired":true,"shares":1071429,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the \"SPA\"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the \"Issuer\") and Syntone Ventures LLC (\"Syntone\"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the \"SPA\"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the \"Issuer\") and Syntone Ventures LLC (\"Syntone\"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024."}],"balance_after":1071429,"derivative":{"exercise_price":7.7,"exercise_date":"2024-04-15","expiration_date":"2029-04-15","underlying":"Common Stock","underlying_shares":1071429},"source":{"system":"sec-edgar","filing":"0001415889-24-011064","document":"form4-04182024_120410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814394/000141588924011064/form4-04182024_120410.xml","form_type":"4"}},{"id":1540057,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":91943,"kind":"organization","name":"Syntone Ventures LLC","position":1,"cik":"0001814394","reported_name":"Syntone Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-17T20:21:17.000Z","date":"2024-04-15","kind":"purchase","planned":false,"acquired":true,"shares":714286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the \"SPA\"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the \"Issuer\") and Syntone Ventures LLC (\"Syntone\"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the \"SPA\"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the \"Issuer\") and Syntone Ventures LLC (\"Syntone\"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective March 14, 2024, every 20 issued and outstanding shares of the Issuer's common stock was automatically combined into one issued and outstanding share of the Issuer's common stock (the \"Reverse Stock Split\"). Prior to the Reverse Stock Split, Syntone held 19,823,045 shares of common stock and, as a result of the Reverse Stock Split, such shares of common stock became 991,152 shares of common stock."}],"balance_after":1705438,"source":{"system":"sec-edgar","filing":"0001415889-24-011064","document":"form4-04182024_120410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814394/000141588924011064/form4-04182024_120410.xml","form_type":"4"}},{"id":1557416,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-29T14:39:09.000Z","date":"2024-03-28","kind":"purchase","planned":false,"acquired":true,"shares":1881.7112,"price":11.82,"value":22241.826384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $11.78 to $11.8249 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024."}],"balance_after":5048.7112,"source":{"system":"sec-edgar","filing":"0001415889-24-009394","document":"form4-03292024_020304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924009394/form4-03292024_020304.xml","form_type":"4"}},{"id":1563197,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23282,"kind":"person","name":"KENYON LAWRENCE A","position":1,"cik":"0001230484","reported_name":"KENYON LAWRENCE A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-22T21:00:22.000Z","date":"2024-03-20","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances."}],"balance_after":12500,"derivative":{"exercise_price":6.78,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-008974","document":"form4-03222024_050315.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230484/000141588924008974/form4-03222024_050315.xml","form_type":"4"}},{"id":1563205,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":92745,"kind":"person","name":"TRENARY C RUSSELL III","position":1,"cik":"0001227307","reported_name":"TRENARY C RUSSELL III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-22T17:00:28.000Z","date":"2024-03-20","kind":"grant","planned":false,"acquired":true,"shares":455000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances."}],"balance_after":455000,"derivative":{"exercise_price":6.78,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":455000},"source":{"system":"sec-edgar","filing":"0001415889-24-008973","document":"form4-03222024_050307.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227307/000141588924008973/form4-03222024_050307.xml","form_type":"4"}},{"id":1563438,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":92753,"kind":"person","name":"Evanson Jeff","position":1,"cik":"0001760511","reported_name":"Evanson Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-22T17:00:24.000Z","date":"2024-03-20","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances."}],"balance_after":25000,"derivative":{"exercise_price":6.78,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-008975","document":"form4-03222024_050317.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760511/000141588924008975/form4-03222024_050317.xml","form_type":"4"}},{"id":1566102,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-03-20T21:20:14.000Z","date":"2024-03-18","kind":"grant","planned":false,"acquired":true,"shares":3458571,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the \"SPA\"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, including GMS Ventures and Investments (\"GMS Ventures\"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, the purchase by GMS Ventures of 2,305,714 shares of common stock and warrants to acquire 3,458,571 shares of common stock closed on March 18, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the \"SPA\"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, including GMS Ventures and Investments (\"GMS Ventures\"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, the purchase by GMS Ventures of 2,305,714 shares of common stock and warrants to acquire 3,458,571 shares of common stock closed on March 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3458571,"derivative":{"exercise_price":7.7,"exercise_date":"2024-03-18","expiration_date":"2029-03-18","underlying":"Common Stock","underlying_shares":3458571},"source":{"system":"sec-edgar","filing":"0000947871-24-000291","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787124000291/ownership.xml","form_type":"4"}},{"id":1566101,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":23366,"kind":"person","name":"Sukhtian Ghiath M.","position":1,"cik":"0001717441","reported_name":"Sukhtian Ghiath M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23367,"kind":"person","name":"GMS Ventures & Investments","position":2,"cik":"0001804598","reported_name":"GMS Ventures & Investments","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-20T21:20:14.000Z","date":"2024-03-18","kind":"grant","planned":false,"acquired":true,"shares":2305714,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the \"SPA\"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, including GMS Ventures and Investments (\"GMS Ventures\"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, the purchase by GMS Ventures of 2,305,714 shares of common stock and warrants to acquire 3,458,571 shares of common stock closed on March 18, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the \"SPA\"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, including GMS Ventures and Investments (\"GMS Ventures\"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, the purchase by GMS Ventures of 2,305,714 shares of common stock and warrants to acquire 3,458,571 shares of common stock closed on March 18, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective March 14, 2024, every 20 issued and outstanding shares of the Issuer's common stock was automatically combined into one issued and outstanding share of the Issuer's common stock (the \"Reverse Stock Split\"). Prior to the Reverse Stock Split, GMS Ventures held 70,047,204 shares of common stock and, as a result of the Reverse Stock Split, such shares of common stock became 3,502,360 shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by GMS Ventures. Ghiath M. Sukhtian (\"Ghiath Sukhtian\"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5808074,"source":{"system":"sec-edgar","filing":"0000947871-24-000291","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804598/000094787124000291/ownership.xml","form_type":"4"}},{"id":1584303,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":92753,"kind":"person","name":"Evanson Jeff","position":1,"cik":"0001760511","reported_name":"Evanson Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-11T16:43:10.000Z","date":"2024-03-07","kind":"purchase","planned":false,"acquired":true,"shares":62484,"price":0.42,"value":26243.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.4044 to $0.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":808459,"source":{"system":"sec-edgar","filing":"0001415889-24-007516","document":"form4-03112024_080303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760511/000141588924007516/form4-03112024_080303.xml","form_type":"4"}},{"id":1585937,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":14549,"kind":"person","name":"Haller Julia A","position":1,"cik":"0001656082","reported_name":"Haller Julia A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T21:30:50.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007354","document":"form4-03082024_090336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924007354/form4-03082024_090336.xml","form_type":"4"}},{"id":1585936,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T21:11:11.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007332","document":"form4-03082024_090358.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924007332/form4-03082024_090358.xml","form_type":"4"}},{"id":1585935,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T21:08:43.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007326","document":"form4-03082024_090335.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000141588924007326/form4-03082024_090335.xml","form_type":"4"}},{"id":1586331,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":33645,"kind":"person","name":"HILZINGER KURT J","position":1,"cik":"0001191504","reported_name":"HILZINGER KURT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T21:06:59.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007324","document":"form4-03082024_090353.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191504/000141588924007324/form4-03082024_090353.xml","form_type":"4"}},{"id":1586330,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":43781,"kind":"person","name":"THURMAN RANDY H","position":1,"cik":"0001204059","reported_name":"THURMAN RANDY H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T21:04:31.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007319","document":"form4-03082024_090322.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1204059/000141588924007319/form4-03082024_090322.xml","form_type":"4"}},{"id":1586970,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74560,"kind":"person","name":"Huang Andong","position":1,"cik":"0001815678","reported_name":"Huang Andong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T16:18:39.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007342","document":"form4-03082024_090327.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815678/000141588924007342/form4-03082024_090327.xml","form_type":"4"}},{"id":1586736,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74553,"kind":"person","name":"Auffarth Gerd","position":1,"cik":"0001649867","reported_name":"Auffarth Gerd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T16:14:48.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007338","document":"form4-03082024_090337.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649867/000141588924007338/form4-03082024_090337.xml","form_type":"4"}},{"id":1586098,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T16:13:00.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":94441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":94441,"derivative":{"exercise_price":0.41,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":94441},"source":{"system":"sec-edgar","filing":"0001415889-24-007335","document":"form4-03082024_090352.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000141588924007335/form4-03082024_090352.xml","form_type":"4"}},{"id":1763354,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74543,"kind":"person","name":"Gangolli Julian S","position":1,"cik":"0001532023","reported_name":"Gangolli Julian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-06T08:16:11.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":370282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":370282,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":370282},"source":{"system":"sec-edgar","filing":"0001209191-23-052271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532023/000120919123052271/doc4.xml","form_type":"4"}},{"id":1764193,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":14549,"kind":"person","name":"Haller Julia A","position":1,"cik":"0001656082","reported_name":"Haller Julia A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T21:15:43.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":210225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":210225,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":210225},"source":{"system":"sec-edgar","filing":"0001209191-23-052240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919123052240/doc4.xml","form_type":"4"}},{"id":1764192,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T21:07:18.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":358337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $75,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":358337,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":358337},"source":{"system":"sec-edgar","filing":"0001209191-23-052235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919123052235/doc4.xml","form_type":"4"}},{"id":1764191,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T21:06:18.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":372671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $78,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":372671,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":372671},"source":{"system":"sec-edgar","filing":"0001209191-23-052233","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919123052233/doc4.xml","form_type":"4"}},{"id":1764281,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":33645,"kind":"person","name":"HILZINGER KURT J","position":1,"cik":"0001191504","reported_name":"HILZINGER KURT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T21:05:23.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":286670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":286670,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":286670},"source":{"system":"sec-edgar","filing":"0001209191-23-052232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191504/000120919123052232/doc4.xml","form_type":"4"}},{"id":1764368,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74560,"kind":"person","name":"Huang Andong","position":1,"cik":"0001815678","reported_name":"Huang Andong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T17:14:47.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":191113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $40,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":191113,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":191113},"source":{"system":"sec-edgar","filing":"0001209191-23-052239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815678/000120919123052239/doc4.xml","form_type":"4"}},{"id":1764335,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":74553,"kind":"person","name":"Auffarth Gerd","position":1,"cik":"0001649867","reported_name":"Auffarth Gerd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-05T17:13:43.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":210225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan."}],"balance_after":210225,"derivative":{"exercise_price":0.24,"expiration_date":"2033-10-04","underlying":"Common Stock","underlying_shares":210225},"source":{"system":"sec-edgar","filing":"0001209191-23-052238","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649867/000120919123052238/doc4.xml","form_type":"4"}},{"id":1915639,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":114287,"kind":"person","name":"Dagnon Terry","position":1,"cik":"0001760510","reported_name":"Dagnon Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2023-04-21T21:05:47.000Z","date":"2023-04-20","kind":"sale","planned":false,"acquired":false,"shares":520000,"price":1.135,"value":590200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020."}],"balance_after":653058,"source":{"system":"sec-edgar","filing":"0001209191-23-025294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760510/000120919123025294/doc4.xml","form_type":"4"}},{"id":1917260,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":114287,"kind":"person","name":"Dagnon Terry","position":1,"cik":"0001760510","reported_name":"Dagnon Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-19T17:41:39.000Z","date":"2023-04-17","kind":"grant","planned":false,"acquired":true,"shares":192143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances."}],"balance_after":192143,"derivative":{"exercise_price":1.08,"expiration_date":"2033-04-17","underlying":"Common Stock","underlying_shares":192143},"source":{"system":"sec-edgar","filing":"0001209191-23-024881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760510/000120919123024881/doc4.xml","form_type":"4"}},{"id":1917259,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":92753,"kind":"person","name":"Evanson Jeff","position":1,"cik":"0001760511","reported_name":"Evanson Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-19T17:41:00.000Z","date":"2023-04-17","kind":"grant","planned":false,"acquired":true,"shares":192143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances."}],"balance_after":192143,"derivative":{"exercise_price":1.08,"expiration_date":"2033-04-17","underlying":"Common Stock","underlying_shares":192143},"source":{"system":"sec-edgar","filing":"0001209191-23-024880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760511/000120919123024880/doc4.xml","form_type":"4"}},{"id":1917080,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":92745,"kind":"person","name":"TRENARY C RUSSELL III","position":1,"cik":"0001227307","reported_name":"TRENARY C RUSSELL III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-19T17:40:03.000Z","date":"2023-04-17","kind":"grant","planned":false,"acquired":true,"shares":257143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances."}],"balance_after":257143,"derivative":{"exercise_price":1.08,"expiration_date":"2033-04-17","underlying":"Common Stock","underlying_shares":257143},"source":{"system":"sec-edgar","filing":"0001209191-23-024879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227307/000120919123024879/doc4.xml","form_type":"4"}},{"id":1933736,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":41619,"kind":"person","name":"Haddadin Yezan Munther","position":1,"cik":"0001718004","reported_name":"Haddadin Yezan Munther","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-31T21:50:58.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":41065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":41065,"derivative":{"exercise_price":1.05,"expiration_date":"2033-03-29","underlying":"Common Stock","underlying_shares":41065},"source":{"system":"sec-edgar","filing":"0001209191-23-021913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919123021913/doc4.xml","form_type":"4"}},{"id":1933735,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":14549,"kind":"person","name":"Haller Julia A","position":1,"cik":"0001656082","reported_name":"Haller Julia A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-31T21:49:59.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":41065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":41065,"derivative":{"exercise_price":1.05,"expiration_date":"2033-03-29","underlying":"Common Stock","underlying_shares":41065},"source":{"system":"sec-edgar","filing":"0001209191-23-021912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919123021912/doc4.xml","form_type":"4"}},{"id":1933734,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":27971,"kind":"person","name":"Sukhtian Faisal Ghiath","position":1,"cik":"0001716033","reported_name":"Sukhtian Faisal Ghiath","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-31T21:45:38.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":41065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted under the Issuer's 2015 Equity Incentive Plan (the \"2015 Plan\") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control."}],"balance_after":41065,"derivative":{"exercise_price":1.05,"expiration_date":"2033-03-29","underlying":"Common Stock","underlying_shares":41065},"source":{"system":"sec-edgar","filing":"0001209191-23-021906","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919123021906/doc4.xml","form_type":"4"}}],"next_cursor":"2023-03-31T21:45:38.000000Z,1933734"}